| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 18 | 2025 | 246 | 3.680 |
Why?
|
| Tumor Suppressor Proteins | 28 | 2015 | 493 | 3.220 |
Why?
|
| Histone-Lysine N-Methyltransferase | 10 | 2021 | 172 | 3.110 |
Why?
|
| Leiomyoma | 20 | 2024 | 83 | 3.090 |
Why?
|
| Kidney Neoplasms | 20 | 2025 | 454 | 3.030 |
Why?
|
| Uterine Neoplasms | 19 | 2024 | 112 | 2.850 |
Why?
|
| Epigenesis, Genetic | 21 | 2024 | 757 | 2.400 |
Why?
|
| Peroxisomes | 5 | 2018 | 42 | 2.370 |
Why?
|
| Autophagy | 13 | 2020 | 427 | 2.120 |
Why?
|
| Endocrine Disruptors | 11 | 2024 | 53 | 1.990 |
Why?
|
| TOR Serine-Threonine Kinases | 19 | 2015 | 446 | 1.850 |
Why?
|
| Signal Transduction | 34 | 2019 | 4725 | 1.790 |
Why?
|
| DNA-Binding Proteins | 8 | 2025 | 1997 | 1.780 |
Why?
|
| Reactive Oxygen Species | 8 | 2018 | 515 | 1.730 |
Why?
|
| Prenatal Exposure Delayed Effects | 6 | 2019 | 242 | 1.450 |
Why?
|
| Carcinoma, Medullary | 6 | 2025 | 15 | 1.440 |
Why?
|
| Lysine | 5 | 2020 | 190 | 1.300 |
Why?
|
| Estrogens | 9 | 2014 | 435 | 1.270 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 6 | 2016 | 100 | 1.200 |
Why?
|
| Actins | 2 | 2020 | 337 | 1.150 |
Why?
|
| Animals | 86 | 2025 | 34953 | 1.100 |
Why?
|
| Histones | 11 | 2021 | 538 | 1.090 |
Why?
|
| Rats | 37 | 2023 | 3612 | 1.060 |
Why?
|
| Autism Spectrum Disorder | 10 | 2025 | 430 | 1.040 |
Why?
|
| Environmental Exposure | 13 | 2025 | 234 | 1.040 |
Why?
|
| Protein Kinases | 6 | 2010 | 331 | 1.000 |
Why?
|
| Multiprotein Complexes | 7 | 2015 | 201 | 0.990 |
Why?
|
| Placenta | 11 | 2025 | 542 | 0.980 |
Why?
|
| SMARCB1 Protein | 5 | 2025 | 48 | 0.970 |
Why?
|
| Cell Cycle Proteins | 5 | 2017 | 686 | 0.910 |
Why?
|
| Disease Susceptibility | 5 | 2019 | 292 | 0.900 |
Why?
|
| Endometrial Neoplasms | 5 | 2010 | 112 | 0.890 |
Why?
|
| Repressor Proteins | 10 | 2005 | 815 | 0.890 |
Why?
|
| Epigenomics | 8 | 2025 | 190 | 0.890 |
Why?
|
| Receptors, Estrogen | 4 | 2013 | 741 | 0.870 |
Why?
|
| Microtubules | 6 | 2021 | 131 | 0.870 |
Why?
|
| Cytoplasm | 4 | 2011 | 270 | 0.870 |
Why?
|
| Diethylstilbestrol | 4 | 2010 | 45 | 0.840 |
Why?
|
| DNA Helicases | 1 | 2025 | 241 | 0.830 |
Why?
|
| Cytoskeleton | 4 | 2021 | 171 | 0.820 |
Why?
|
| Environmental Pollutants | 5 | 2021 | 78 | 0.810 |
Why?
|
| Tubulin | 3 | 2021 | 76 | 0.800 |
Why?
|
| Methylation | 9 | 2021 | 216 | 0.800 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 4 | 2011 | 60 | 0.760 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2018 | 634 | 0.730 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2025 | 2064 | 0.710 |
Why?
|
| Gene Expression Regulation, Developmental | 5 | 2016 | 1019 | 0.700 |
Why?
|
| Proteostasis | 2 | 2019 | 36 | 0.690 |
Why?
|
| Humans | 108 | 2025 | 132105 | 0.690 |
Why?
|
| Phosphorylation | 17 | 2016 | 1613 | 0.670 |
Why?
|
| Mutation, Missense | 1 | 2025 | 938 | 0.660 |
Why?
|
| Estrogens, Non-Steroidal | 5 | 2017 | 17 | 0.660 |
Why?
|
| Transcription Factors | 6 | 2022 | 2494 | 0.660 |
Why?
|
| Cardiomyopathies | 1 | 2025 | 510 | 0.660 |
Why?
|
| GTP-Binding Proteins | 1 | 2020 | 173 | 0.640 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2010 | 503 | 0.640 |
Why?
|
| Myometrium | 7 | 2024 | 47 | 0.640 |
Why?
|
| Polycystic Kidney Diseases | 3 | 2006 | 32 | 0.630 |
Why?
|
| Membrane Proteins | 6 | 2020 | 1597 | 0.620 |
Why?
|
| Proteomics | 2 | 2023 | 594 | 0.620 |
Why?
|
| Transcriptome | 3 | 2024 | 1124 | 0.620 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2020 | 258 | 0.600 |
Why?
|
| Mice, Inbred C57BL | 7 | 2024 | 4764 | 0.600 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2016 | 343 | 0.590 |
Why?
|
| Insulin Receptor Substrate Proteins | 4 | 2019 | 78 | 0.580 |
Why?
|
| Immunohistochemistry | 7 | 2016 | 1723 | 0.580 |
Why?
|
| 14-3-3 Proteins | 4 | 2016 | 57 | 0.570 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2015 | 326 | 0.570 |
Why?
|
| Macaca mulatta | 2 | 2022 | 506 | 0.560 |
Why?
|
| Histone Code | 3 | 2019 | 51 | 0.560 |
Why?
|
| Microbiota | 1 | 2023 | 434 | 0.550 |
Why?
|
| Adiposity | 2 | 2020 | 207 | 0.550 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 3698 | 0.540 |
Why?
|
| Hydrocortisone | 1 | 2018 | 226 | 0.540 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2014 | 37 | 0.540 |
Why?
|
| Female | 70 | 2025 | 70680 | 0.530 |
Why?
|
| MCF-7 Cells | 8 | 2017 | 217 | 0.520 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2021 | 119 | 0.520 |
Why?
|
| Gene-Environment Interaction | 3 | 2020 | 130 | 0.520 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2009 | 256 | 0.520 |
Why?
|
| Social Behavior | 1 | 2018 | 225 | 0.500 |
Why?
|
| Homeostasis | 2 | 2018 | 723 | 0.500 |
Why?
|
| DNA Methylation | 11 | 2022 | 1130 | 0.500 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2013 | 175 | 0.500 |
Why?
|
| Autistic Disorder | 5 | 2022 | 387 | 0.500 |
Why?
|
| Cell Line | 10 | 2020 | 2730 | 0.490 |
Why?
|
| Organelles | 1 | 2016 | 23 | 0.490 |
Why?
|
| Mice | 28 | 2025 | 18566 | 0.490 |
Why?
|
| Endometrial Hyperplasia | 3 | 2010 | 18 | 0.490 |
Why?
|
| Behavior, Animal | 2 | 2018 | 506 | 0.490 |
Why?
|
| Prostatic Neoplasms | 3 | 2016 | 1578 | 0.480 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 74 | 0.480 |
Why?
|
| Genes, Tumor Suppressor | 7 | 2006 | 210 | 0.470 |
Why?
|
| Methyltransferases | 1 | 2016 | 82 | 0.470 |
Why?
|
| Emotions | 1 | 2018 | 367 | 0.470 |
Why?
|
| Reproduction | 3 | 2008 | 226 | 0.470 |
Why?
|
| Pregnancy | 26 | 2025 | 7551 | 0.470 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 6 | 2015 | 167 | 0.470 |
Why?
|
| Blotting, Western | 9 | 2016 | 1085 | 0.460 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 455 | 0.460 |
Why?
|
| Anemia, Sickle Cell | 2 | 2018 | 344 | 0.450 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 1396 | 0.450 |
Why?
|
| beta Catenin | 2 | 2014 | 228 | 0.440 |
Why?
|
| Aurora Kinase A | 1 | 2014 | 37 | 0.440 |
Why?
|
| Protein Processing, Post-Translational | 5 | 2021 | 365 | 0.430 |
Why?
|
| Disease Models, Animal | 11 | 2025 | 4694 | 0.420 |
Why?
|
| Adenylate Kinase | 2 | 2010 | 13 | 0.410 |
Why?
|
| Hormones | 3 | 2016 | 170 | 0.410 |
Why?
|
| Cell Membrane | 5 | 2016 | 473 | 0.400 |
Why?
|
| Genomic Instability | 4 | 2025 | 248 | 0.400 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 1038 | 0.390 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 701 | 0.390 |
Why?
|
| Maternal Exposure | 4 | 2019 | 156 | 0.380 |
Why?
|
| Biomarkers | 8 | 2025 | 3380 | 0.380 |
Why?
|
| Mitochondria | 1 | 2018 | 752 | 0.380 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 246 | 0.380 |
Why?
|
| TRPP Cation Channels | 2 | 2010 | 4 | 0.380 |
Why?
|
| Genistein | 1 | 2012 | 39 | 0.370 |
Why?
|
| Mitosis | 4 | 2025 | 201 | 0.360 |
Why?
|
| Genitalia, Male | 1 | 2011 | 35 | 0.350 |
Why?
|
| Phenols | 4 | 2017 | 57 | 0.350 |
Why?
|
| Cells | 1 | 2011 | 24 | 0.350 |
Why?
|
| Multienzyme Complexes | 2 | 2008 | 85 | 0.350 |
Why?
|
| Genitalia, Female | 1 | 2011 | 46 | 0.340 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1683 | 0.340 |
Why?
|
| Benzhydryl Compounds | 4 | 2017 | 68 | 0.340 |
Why?
|
| Protein Binding | 6 | 2021 | 1735 | 0.340 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 1292 | 0.340 |
Why?
|
| HEK293 Cells | 5 | 2016 | 796 | 0.330 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 579 | 0.330 |
Why?
|
| Tumor Cells, Cultured | 10 | 2020 | 1047 | 0.330 |
Why?
|
| Cyclonic Storms | 2 | 2021 | 79 | 0.320 |
Why?
|
| Disasters | 2 | 2021 | 105 | 0.320 |
Why?
|
| Male | 32 | 2025 | 64918 | 0.310 |
Why?
|
| Carcinogens | 3 | 2008 | 129 | 0.310 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 39 | 0.300 |
Why?
|
| Trans-Activators | 2 | 2003 | 714 | 0.300 |
Why?
|
| Uterus | 3 | 2010 | 547 | 0.300 |
Why?
|
| Polychlorinated Biphenyls | 2 | 2021 | 12 | 0.290 |
Why?
|
| Kidney | 5 | 2023 | 1333 | 0.290 |
Why?
|
| Mice, Knockout | 10 | 2019 | 3873 | 0.280 |
Why?
|
| Carcinoma | 1 | 2010 | 300 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2008 | 3358 | 0.270 |
Why?
|
| Extracellular Matrix | 3 | 2024 | 238 | 0.270 |
Why?
|
| Sirolimus | 5 | 2010 | 241 | 0.270 |
Why?
|
| Quinoxalines | 1 | 2007 | 38 | 0.260 |
Why?
|
| Activin Receptors, Type I | 1 | 2007 | 35 | 0.260 |
Why?
|
| Infertility, Female | 1 | 2008 | 149 | 0.260 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2007 | 106 | 0.260 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2004 | 53 | 0.260 |
Why?
|
| Proteins | 5 | 2010 | 1038 | 0.250 |
Why?
|
| Trichloroethylene | 1 | 2006 | 2 | 0.250 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2014 | 101 | 0.250 |
Why?
|
| Solvents | 1 | 2006 | 46 | 0.250 |
Why?
|
| Hydrogen Peroxide | 2 | 2018 | 124 | 0.250 |
Why?
|
| Imidazoles | 1 | 2007 | 219 | 0.240 |
Why?
|
| Haploinsufficiency | 2 | 2025 | 270 | 0.240 |
Why?
|
| Centrosome | 1 | 2025 | 27 | 0.240 |
Why?
|
| Cysteine | 1 | 2006 | 142 | 0.240 |
Why?
|
| CA-125 Antigen | 1 | 2025 | 15 | 0.230 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2025 | 35 | 0.230 |
Why?
|
| Cellular Reprogramming | 3 | 2016 | 130 | 0.230 |
Why?
|
| Rats, Mutant Strains | 6 | 2010 | 15 | 0.230 |
Why?
|
| High-Throughput Screening Assays | 2 | 2017 | 109 | 0.230 |
Why?
|
| Chromatin | 4 | 2025 | 521 | 0.230 |
Why?
|
| Trialkyltin Compounds | 1 | 2024 | 7 | 0.230 |
Why?
|
| Penetrance | 1 | 2005 | 113 | 0.230 |
Why?
|
| Vitamins | 1 | 2025 | 111 | 0.220 |
Why?
|
| Estradiol | 5 | 2010 | 488 | 0.220 |
Why?
|
| Liver | 4 | 2024 | 1806 | 0.210 |
Why?
|
| Isochromosomes | 1 | 2023 | 17 | 0.210 |
Why?
|
| Anxiety | 2 | 2021 | 1002 | 0.210 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 79 | 0.210 |
Why?
|
| Biological Assay | 2 | 2016 | 111 | 0.200 |
Why?
|
| Sickle Cell Trait | 1 | 2023 | 11 | 0.200 |
Why?
|
| Vascular Neoplasms | 1 | 2003 | 33 | 0.200 |
Why?
|
| Patient Selection | 2 | 2018 | 732 | 0.200 |
Why?
|
| Tuberous Sclerosis | 4 | 2010 | 124 | 0.200 |
Why?
|
| Cells, Cultured | 6 | 2017 | 3061 | 0.200 |
Why?
|
| Environmental Health | 1 | 2023 | 16 | 0.200 |
Why?
|
| Receptors, Progesterone | 2 | 2007 | 681 | 0.200 |
Why?
|
| Genes, cdc | 1 | 2003 | 25 | 0.200 |
Why?
|
| Thiophenes | 1 | 2003 | 69 | 0.200 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2002 | 53 | 0.200 |
Why?
|
| Carcinogenesis | 4 | 2023 | 359 | 0.200 |
Why?
|
| Mothers | 2 | 2016 | 372 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 1 | 2003 | 66 | 0.190 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 81 | 0.190 |
Why?
|
| Serine | 2 | 2015 | 166 | 0.190 |
Why?
|
| DNA Replication | 2 | 2023 | 353 | 0.190 |
Why?
|
| Adult | 17 | 2025 | 31557 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 61 | 0.180 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 1018 | 0.180 |
Why?
|
| Lymphangioleiomyomatosis | 3 | 2010 | 16 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2025 | 439 | 0.180 |
Why?
|
| Prostate | 2 | 2015 | 437 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 265 | 0.180 |
Why?
|
| Piperidines | 1 | 2003 | 236 | 0.180 |
Why?
|
| Tamoxifen | 1 | 2003 | 354 | 0.180 |
Why?
|
| Microscopy, Fluorescence | 3 | 2015 | 329 | 0.180 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2012 | 29 | 0.180 |
Why?
|
| Chromosome Aberrations | 2 | 2023 | 591 | 0.170 |
Why?
|
| Deer | 1 | 2021 | 14 | 0.170 |
Why?
|
| RNA Interference | 2 | 2015 | 516 | 0.170 |
Why?
|
| Models, Biological | 5 | 2016 | 1441 | 0.170 |
Why?
|
| Floods | 1 | 2021 | 18 | 0.170 |
Why?
|
| Risk Factors | 10 | 2018 | 10902 | 0.170 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2012 | 67 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1306 | 0.170 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 691 | 0.170 |
Why?
|
| Sequence Deletion | 1 | 2003 | 527 | 0.170 |
Why?
|
| Autophagy-Related Proteins | 1 | 2020 | 35 | 0.170 |
Why?
|
| Disaster Planning | 1 | 2021 | 60 | 0.170 |
Why?
|
| Catalytic Domain | 1 | 2021 | 180 | 0.170 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 282 | 0.170 |
Why?
|
| Hypoxia | 2 | 2023 | 259 | 0.170 |
Why?
|
| Reading | 1 | 2021 | 79 | 0.170 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 138 | 0.160 |
Why?
|
| Organotin Compounds | 1 | 2020 | 6 | 0.160 |
Why?
|
| Loss of Heterozygosity | 4 | 2009 | 130 | 0.160 |
Why?
|
| Phenotype | 3 | 2025 | 4541 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 1829 | 0.160 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2016 | 295 | 0.160 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2019 | 6 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2002 | 615 | 0.160 |
Why?
|
| Antibodies | 2 | 2016 | 367 | 0.160 |
Why?
|
| HeLa Cells | 5 | 2017 | 732 | 0.160 |
Why?
|
| Health Promotion | 1 | 2023 | 399 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2016 | 1225 | 0.160 |
Why?
|
| Cell Division | 5 | 2003 | 744 | 0.150 |
Why?
|
| Halogenated Diphenyl Ethers | 2 | 2021 | 11 | 0.150 |
Why?
|
| Pregnancy Complications | 2 | 2021 | 550 | 0.150 |
Why?
|
| Gene Deletion | 2 | 2018 | 795 | 0.150 |
Why?
|
| Child Development | 2 | 2024 | 271 | 0.150 |
Why?
|
| Breast Neoplasms | 3 | 2014 | 2683 | 0.150 |
Why?
|
| Depression, Postpartum | 1 | 2019 | 54 | 0.150 |
Why?
|
| Rhabdoid Tumor | 1 | 2019 | 56 | 0.150 |
Why?
|
| Hypersensitivity | 1 | 2021 | 195 | 0.150 |
Why?
|
| Hyperoxia | 1 | 2020 | 130 | 0.140 |
Why?
|
| Eligibility Determination | 1 | 2018 | 38 | 0.140 |
Why?
|
| Carcinogens, Environmental | 2 | 2015 | 13 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2020 | 679 | 0.140 |
Why?
|
| Genomic Imprinting | 1 | 2019 | 130 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2019 | 126 | 0.140 |
Why?
|
| Osmotic Pressure | 1 | 2018 | 24 | 0.140 |
Why?
|
| Immunoblotting | 2 | 2010 | 304 | 0.140 |
Why?
|
| Stress, Psychological | 2 | 2021 | 578 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2018 | 94 | 0.140 |
Why?
|
| Estrogen Receptor beta | 2 | 2017 | 78 | 0.140 |
Why?
|
| Mad2 Proteins | 1 | 2017 | 9 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 30 | 0.140 |
Why?
|
| Breast Feeding | 1 | 2019 | 233 | 0.140 |
Why?
|
| Embryonic Development | 1 | 2019 | 221 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2025 | 5150 | 0.130 |
Why?
|
| PDZ Domains | 1 | 2016 | 10 | 0.130 |
Why?
|
| Rats, Inbred Strains | 2 | 2007 | 219 | 0.130 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2016 | 41 | 0.130 |
Why?
|
| Cell Compartmentation | 1 | 2016 | 41 | 0.130 |
Why?
|
| Transcription, Genetic | 2 | 2017 | 1425 | 0.130 |
Why?
|
| Mutation | 5 | 2021 | 6249 | 0.130 |
Why?
|
| Organ Specificity | 2 | 2011 | 413 | 0.130 |
Why?
|
| Siblings | 3 | 2024 | 202 | 0.130 |
Why?
|
| Fetal Proteins | 1 | 2016 | 13 | 0.130 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 1 | 2016 | 9 | 0.130 |
Why?
|
| Cytokinesis | 1 | 2016 | 22 | 0.130 |
Why?
|
| Apoptosis | 4 | 2020 | 1904 | 0.130 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2016 | 21 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 1554 | 0.120 |
Why?
|
| Protein Array Analysis | 2 | 2009 | 105 | 0.120 |
Why?
|
| Peroxisome-Targeting Signal 1 Receptor | 1 | 2015 | 2 | 0.120 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 236 | 0.120 |
Why?
|
| Sequestosome-1 Protein | 1 | 2015 | 15 | 0.120 |
Why?
|
| Phagosomes | 1 | 2015 | 38 | 0.120 |
Why?
|
| Growth Substances | 2 | 2006 | 109 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 94 | 0.120 |
Why?
|
| Epithelial Cells | 2 | 2014 | 903 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2010 | 799 | 0.120 |
Why?
|
| Growth and Development | 1 | 2015 | 22 | 0.120 |
Why?
|
| Mammaglobin B | 1 | 2015 | 1 | 0.120 |
Why?
|
| Health | 1 | 2015 | 35 | 0.110 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 1097 | 0.110 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 341 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1495 | 0.110 |
Why?
|
| Maternal Behavior | 1 | 2015 | 71 | 0.110 |
Why?
|
| Brain | 4 | 2022 | 3201 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 293 | 0.110 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2005 | 91 | 0.110 |
Why?
|
| Neoplasms | 3 | 2017 | 2953 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 1 | 2015 | 48 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 189 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2017 | 3714 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 2 | 2017 | 439 | 0.110 |
Why?
|
| Mammals | 1 | 2016 | 271 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 774 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 1 | 2015 | 221 | 0.110 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2014 | 14 | 0.110 |
Why?
|
| DNA Damage | 2 | 2023 | 513 | 0.110 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cell Proliferation | 5 | 2020 | 2512 | 0.110 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2014 | 26 | 0.110 |
Why?
|
| DNA Repair | 2 | 2023 | 567 | 0.110 |
Why?
|
| Carotenoids | 1 | 2015 | 79 | 0.110 |
Why?
|
| Gene Expression Profiling | 4 | 2025 | 1879 | 0.110 |
Why?
|
| Cilia | 1 | 2014 | 79 | 0.110 |
Why?
|
| Disease | 1 | 2015 | 126 | 0.100 |
Why?
|
| Fetal Blood | 2 | 2025 | 174 | 0.100 |
Why?
|
| Pesticides | 1 | 2014 | 30 | 0.100 |
Why?
|
| Veterans | 1 | 2025 | 1762 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1158 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2015 | 623 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2022 | 8538 | 0.100 |
Why?
|
| Proteome | 1 | 2015 | 278 | 0.100 |
Why?
|
| Rats, Long-Evans | 2 | 2003 | 102 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2016 | 458 | 0.100 |
Why?
|
| Child, Preschool | 8 | 2025 | 14718 | 0.100 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2014 | 98 | 0.100 |
Why?
|
| Epithelium | 1 | 2014 | 354 | 0.100 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 156 | 0.100 |
Why?
|
| Obesity | 5 | 2021 | 2396 | 0.100 |
Why?
|
| Genome, Human | 3 | 2016 | 1332 | 0.100 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2012 | 5 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 2 | 2023 | 475 | 0.100 |
Why?
|
| Infant | 6 | 2025 | 13039 | 0.100 |
Why?
|
| Misoprostol | 1 | 2012 | 27 | 0.100 |
Why?
|
| Stem Cells | 2 | 2015 | 732 | 0.090 |
Why?
|
| Memory | 1 | 2015 | 355 | 0.090 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 241 | 0.090 |
Why?
|
| Cellular Senescence | 1 | 2014 | 201 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 422 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 663 | 0.090 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2024 | 124 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2025 | 6530 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2009 | 2679 | 0.090 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2011 | 26 | 0.090 |
Why?
|
| Ligands | 2 | 2003 | 495 | 0.090 |
Why?
|
| Neurons | 1 | 2021 | 2016 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2011 | 51 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2012 | 383 | 0.090 |
Why?
|
| Health Personnel | 1 | 2016 | 545 | 0.090 |
Why?
|
| Gene Silencing | 3 | 2015 | 240 | 0.090 |
Why?
|
| California | 3 | 2018 | 140 | 0.090 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 430 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 198 | 0.080 |
Why?
|
| Genotype | 2 | 2010 | 2706 | 0.080 |
Why?
|
| Middle Aged | 7 | 2025 | 28936 | 0.080 |
Why?
|
| Depression | 1 | 2019 | 1351 | 0.080 |
Why?
|
| Microscopy, Confocal | 2 | 2015 | 368 | 0.080 |
Why?
|
| Calcium | 1 | 2015 | 1083 | 0.080 |
Why?
|
| Cell Death | 1 | 2011 | 243 | 0.080 |
Why?
|
| DNA | 3 | 2022 | 1483 | 0.080 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 16 | 0.080 |
Why?
|
| Mercury | 1 | 2010 | 32 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 197 | 0.080 |
Why?
|
| Cadherins | 2 | 2019 | 180 | 0.080 |
Why?
|
| Time Factors | 4 | 2014 | 6445 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2016 | 311 | 0.080 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 41 | 0.080 |
Why?
|
| Thymidine Kinase | 1 | 2009 | 90 | 0.080 |
Why?
|
| Disease Progression | 2 | 2020 | 2227 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2015 | 880 | 0.070 |
Why?
|
| Postpartum Period | 2 | 2021 | 231 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2008 | 90 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 425 | 0.070 |
Why?
|
| COS Cells | 2 | 2021 | 269 | 0.070 |
Why?
|
| Chromones | 1 | 2008 | 26 | 0.070 |
Why?
|
| Genital Diseases, Female | 1 | 2008 | 30 | 0.070 |
Why?
|
| Microsatellite Repeats | 1 | 2009 | 236 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 210 | 0.070 |
Why?
|
| Cytosol | 1 | 2008 | 144 | 0.070 |
Why?
|
| Androstadienes | 1 | 2008 | 52 | 0.070 |
Why?
|
| Fibroblasts | 3 | 2018 | 877 | 0.070 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2008 | 28 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2020 | 757 | 0.070 |
Why?
|
| Morpholines | 1 | 2008 | 67 | 0.070 |
Why?
|
| Benzoates | 1 | 2007 | 22 | 0.070 |
Why?
|
| Animals, Newborn | 3 | 2020 | 1034 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2016 | 2674 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2007 | 57 | 0.070 |
Why?
|
| Calbindins | 1 | 2007 | 17 | 0.070 |
Why?
|
| Endometrium | 1 | 2010 | 274 | 0.070 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2007 | 24 | 0.070 |
Why?
|
| Genome-Wide Association Study | 3 | 2020 | 1830 | 0.070 |
Why?
|
| Ribosomal Protein S6 Kinases | 2 | 2008 | 50 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 463 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2007 | 164 | 0.060 |
Why?
|
| Kidney Tubules | 1 | 2007 | 74 | 0.060 |
Why?
|
| Glutamates | 1 | 2007 | 69 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2007 | 131 | 0.060 |
Why?
|
| Menstrual Cycle | 1 | 2007 | 36 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 3982 | 0.060 |
Why?
|
| Carcinogenicity Tests | 1 | 2006 | 21 | 0.060 |
Why?
|
| Kidney Cortex | 1 | 2006 | 19 | 0.060 |
Why?
|
| Cell Survival | 1 | 2009 | 869 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2003 | 52 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2009 | 596 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 323 | 0.060 |
Why?
|
| Endothelial Growth Factors | 2 | 2003 | 53 | 0.060 |
Why?
|
| Lymphokines | 2 | 2003 | 66 | 0.060 |
Why?
|
| Overweight | 2 | 2021 | 383 | 0.060 |
Why?
|
| Prognosis | 3 | 2020 | 5008 | 0.060 |
Why?
|
| Risk | 2 | 2019 | 761 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 1541 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2008 | 595 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 1046 | 0.060 |
Why?
|
| Chromosome Segregation | 1 | 2025 | 73 | 0.060 |
Why?
|
| Adenoma | 1 | 2007 | 145 | 0.060 |
Why?
|
| Base Sequence | 2 | 2015 | 2902 | 0.060 |
Why?
|
| ras Proteins | 1 | 2006 | 146 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2008 | 636 | 0.060 |
Why?
|
| Microscopy | 2 | 2017 | 126 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 589 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3418 | 0.060 |
Why?
|
| Acetylation | 2 | 2015 | 191 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2007 | 368 | 0.060 |
Why?
|
| Serum Response Factor | 1 | 2024 | 29 | 0.050 |
Why?
|
| Prevalence | 2 | 2016 | 2659 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 2453 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2009 | 720 | 0.050 |
Why?
|
| Diabetes, Gestational | 2 | 2016 | 114 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2004 | 77 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 825 | 0.050 |
Why?
|
| Streptozocin | 1 | 2003 | 26 | 0.050 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2003 | 24 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 399 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2023 | 16 | 0.050 |
Why?
|
| Centromere | 1 | 2023 | 72 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 672 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2003 | 444 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 69 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 608 | 0.050 |
Why?
|
| Prostaglandin D2 | 1 | 2003 | 4 | 0.050 |
Why?
|
| Chromans | 1 | 2003 | 8 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2003 | 89 | 0.050 |
Why?
|
| Embryo, Mammalian | 2 | 2017 | 460 | 0.050 |
Why?
|
| United States | 4 | 2025 | 11627 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 2444 | 0.050 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2003 | 28 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 278 | 0.050 |
Why?
|
| Carboplatin | 1 | 2023 | 85 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 946 | 0.050 |
Why?
|
| Receptors, Oxytocin | 1 | 2003 | 21 | 0.050 |
Why?
|
| Connexin 43 | 1 | 2003 | 34 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 66 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2003 | 253 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2002 | 124 | 0.050 |
Why?
|
| Estrous Cycle | 1 | 2002 | 36 | 0.050 |
Why?
|
| Progestins | 1 | 2002 | 45 | 0.050 |
Why?
|
| CpG Islands | 2 | 2015 | 345 | 0.050 |
Why?
|
| HMGA2 Protein | 1 | 2002 | 11 | 0.050 |
Why?
|
| Ultrasonic Therapy | 1 | 2002 | 28 | 0.050 |
Why?
|
| Thiazoles | 1 | 2003 | 99 | 0.050 |
Why?
|
| Karyotyping | 1 | 2003 | 319 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2002 | 30 | 0.050 |
Why?
|
| Metabolome | 1 | 2025 | 323 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2002 | 201 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 288 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2022 | 47 | 0.050 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2002 | 69 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2002 | 301 | 0.050 |
Why?
|
| Ribosomal Proteins | 1 | 2002 | 73 | 0.050 |
Why?
|
| Hydroquinones | 2 | 2017 | 11 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 637 | 0.050 |
Why?
|
| Cell Adhesion | 1 | 2002 | 327 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2003 | 422 | 0.050 |
Why?
|
| Progesterone | 1 | 2004 | 450 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2007 | 784 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 131 | 0.050 |
Why?
|
| Cell Movement | 2 | 2002 | 891 | 0.050 |
Why?
|
| Kidney Diseases | 1 | 2006 | 488 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2025 | 663 | 0.040 |
Why?
|
| Reference Values | 1 | 2003 | 704 | 0.040 |
Why?
|
| Heterozygote | 1 | 2003 | 716 | 0.040 |
Why?
|
| Incidence | 1 | 2009 | 3365 | 0.040 |
Why?
|
| Sociological Factors | 1 | 2021 | 9 | 0.040 |
Why?
|
| Industry | 1 | 2021 | 29 | 0.040 |
Why?
|
| Glutathione | 1 | 2002 | 200 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2002 | 365 | 0.040 |
Why?
|
| Goals | 1 | 2021 | 134 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 764 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 998 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2003 | 381 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 3778 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2021 | 139 | 0.040 |
Why?
|
| Enzyme Activation | 3 | 2011 | 618 | 0.040 |
Why?
|
| Metabolomics | 1 | 2024 | 473 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2020 | 49 | 0.040 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2020 | 38 | 0.040 |
Why?
|
| Toxicity Tests | 1 | 2020 | 35 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2018 | 17374 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2009 | 200 | 0.040 |
Why?
|
| Binding Sites | 1 | 2002 | 1256 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 66 | 0.040 |
Why?
|
| Bottle Feeding | 1 | 2019 | 39 | 0.040 |
Why?
|
| Oogenesis | 1 | 2019 | 55 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2019 | 61 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2019 | 99 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 65 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 9940 | 0.040 |
Why?
|
| Myocardium | 1 | 2003 | 908 | 0.040 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2018 | 7 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 114 | 0.040 |
Why?
|
| National Institute of Environmental Health Sciences (U.S.) | 1 | 2018 | 2 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2019 | 223 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 2018 | 59 | 0.040 |
Why?
|
| Chorionic Villi | 1 | 2017 | 22 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2018 | 74 | 0.030 |
Why?
|
| Photography | 1 | 2018 | 87 | 0.030 |
Why?
|
| Child | 4 | 2022 | 25758 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2019 | 158 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2017 | 61 | 0.030 |
Why?
|
| Organ Size | 1 | 2018 | 447 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1672 | 0.030 |
Why?
|
| Aged | 3 | 2025 | 21413 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 156 | 0.030 |
Why?
|
| Oocytes | 1 | 2019 | 291 | 0.030 |
Why?
|
| Aneuploidy | 1 | 2017 | 144 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 62 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1246 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2017 | 322 | 0.030 |
Why?
|
| Cytokines | 1 | 2022 | 1367 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2016 | 118 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2016 | 77 | 0.030 |
Why?
|
| Cell Count | 1 | 2016 | 234 | 0.030 |
Why?
|
| Lung | 2 | 2020 | 1556 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2019 | 771 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 316 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 855 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 198 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 688 | 0.030 |
Why?
|
| Stromal Interaction Molecule 1 | 1 | 2015 | 9 | 0.030 |
Why?
|
| Embryology | 1 | 2015 | 1 | 0.030 |
Why?
|
| Trypsin | 1 | 2015 | 89 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 1305 | 0.030 |
Why?
|
| Steroids | 1 | 2016 | 173 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1451 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 122 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 333 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 604 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2015 | 21 | 0.030 |
Why?
|
| Adolescent | 3 | 2021 | 20532 | 0.030 |
Why?
|
| Genome | 1 | 2018 | 502 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2017 | 611 | 0.030 |
Why?
|
| Biological Transport | 1 | 2015 | 349 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1035 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2015 | 652 | 0.030 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2015 | 77 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2014 | 21 | 0.030 |
Why?
|
| Ras Homolog Enriched in Brain Protein | 1 | 2014 | 5 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 743 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 122 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2015 | 151 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 348 | 0.030 |
Why?
|
| Telomere | 1 | 2015 | 222 | 0.030 |
Why?
|
| Spermine | 1 | 2013 | 5 | 0.030 |
Why?
|
| Nitric Oxide Donors | 1 | 2013 | 20 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1228 | 0.030 |
Why?
|
| Sulfites | 1 | 2013 | 30 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2015 | 295 | 0.030 |
Why?
|
| Oxygen | 1 | 2016 | 571 | 0.020 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2018 | 553 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 351 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 590 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 699 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2015 | 443 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 3630 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 1651 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 544 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 65 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 806 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 83 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 1294 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1724 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 93 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 470 | 0.020 |
Why?
|
| Everolimus | 1 | 2010 | 50 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2013 | 404 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 1589 | 0.020 |
Why?
|
| Food Contamination | 1 | 2010 | 27 | 0.020 |
Why?
|
| Fishes | 1 | 2010 | 36 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2011 | 303 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 250 | 0.020 |
Why?
|
| Cisplatin | 1 | 2011 | 281 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 402 | 0.020 |
Why?
|
| Aging | 1 | 2016 | 1253 | 0.020 |
Why?
|
| Anoikis | 1 | 2009 | 9 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2009 | 34 | 0.020 |
Why?
|
| Ganciclovir | 1 | 2009 | 101 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 141 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 79 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2009 | 171 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 3021 | 0.020 |
Why?
|
| Benzamides | 1 | 2009 | 124 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 40 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 700 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 118 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 2922 | 0.020 |
Why?
|
| Homozygote | 1 | 2010 | 549 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 137 | 0.020 |
Why?
|
| Gene Expression | 2 | 2003 | 1564 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 50 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 1388 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2007 | 39 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1454 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 196 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 725 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2007 | 751 | 0.010 |
Why?
|
| Developmental Disabilities | 1 | 2010 | 749 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2009 | 1050 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2009 | 822 | 0.010 |
Why?
|
| Cyclooxygenase 1 | 1 | 2003 | 27 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2003 | 70 | 0.010 |
Why?
|
| Ribosomal Protein S6 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 127 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2002 | 18 | 0.010 |
Why?
|
| Oxytocin | 1 | 2003 | 74 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 222 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2002 | 27 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2002 | 113 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2002 | 44 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 53 | 0.010 |
Why?
|
| Dogs | 1 | 2002 | 651 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 999 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 359 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 7119 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2002 | 612 | 0.010 |
Why?
|